Antagonistic Activity of α-Conotoxin TxIB Isomers on Rat and Human α6 /α3β2β3 Nicotinic Acetylcholine Receptors
- Author:
Dong-Ting ZHANGSUN
1
Author Information
- Publication Type:Journal Article
- Keywords: Antagonistic activity; Disulfide bond isomers; Oocytes of Xenopus laevis; Rat and human α6/α3β2β3 nAChRs; α-conotoxin TxIB
- From: Chinese Pharmaceutical Journal 2017;52(7):574-580
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To investigate antagonistic activities of three isomers of α-conotoxin TxIB on rat and human α6 /α3β2β3 nicotinic acetylcholine receptors (nAChRs). METHODS: Three disulfide bond isomers were synthesized using Fmoc chemistry, which were identified by ultra performance liquid chromatography (UPLC)and confirmed by MALDI-TOF mass spectrometry. Rat and human α6/α3β2β3 nAChRs were expressed in oocytes of Xenopus laevis, which were used to test the antagonistic abilities of the 3 isomers. RESULTS: The three isomers of α-conotoxin TxIB were synthesized successfully. The retention time of each isomer of α-conotoxin TxIB was different each other significantly. The observed molecular masses of three isomers were the same, which were consistent with their theoretical molecular mass. Their hydrophilicity orders were globular > ribbon > bead. Both rat and human α6/α3β2β3 nAChRs were expressed in oocytes well. Inhibition of three isomers of α-conotoxin TxIB on rat and human α6 /α3β2β3 nAChRs were evaluated respectively. Among the three isomers of TxIB, the activity of the globular isomer was the most potent one, which had almost same activity at rat and human α6/α3β2β3 nAChRs with corresponding IC50 of 28.2 and 32.0 nmol·L-1 respectively. However, the other two isomers, ribbon and bead isomers displayed little antagonistic effect on both rat and human α6/α3β2β3 nAChRs only with an IC50 of > 10 μmol·L-1. CONCLUSION: The synthesized globular isomer of α-conotoxin TxIB in this work has a high selectivity and potent antagonistic activity on rat and human α6/α3β2β3 nAChRs, which would be helpful for its new drug development.
